A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Celgene
Study ID
NCT02367196
Phase
PHASE1
Status
Completed

Conditions

  • Hematologic Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.

Key Dates

Start date
Mar 12, 2015
Status verified
Aug 2021
Primary completion
Dec 24, 2020
Completion
Dec 24, 2020

Study Design

Enrollment
60 participants (actual)
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: CC-90002
    CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
  • Experimental: Part B: CC-90002 with Rituximab
    CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL

Primary Outcome Measure

Dose-Limiting Toxicity (DLT) [ Time Frame: Up to 18 months ]

Locations (5)

FacilityCityStateZIPSite coordinators
Scottsdale Healthcare Research InstituteScottsdaleArizona85258-
University of Arizona Cancer CenterTucsonArizona85724-
University of California San FranciscoSan FranciscoCalifornia94143-1270-
Yale University School of MedicineNew HavenConnecticut06520-8073-
South Texas Accelerated Research TherapeuticsSan AntonioTexas78229-

Find similar trials in Scottsdale, AZ

By research site
Scottsdale Healthcare Research Institute· Scottsdale, AZUniversity of Arizona Cancer Center· Tucson, AZUniversity of California San Francisco· San Francisco, CAYale University School of Medicine· New Haven, CTSouth Texas Accelerated Research Therapeutics· San Antonio, TX

Related Studies